Transurethral needle ablation of the prostate (TUNA) was heralded as a minimally invasive alternative to transurethral resection of the prostate (TURP), but is now marketed as an alternative to ...

Transperineal laser ablation (TPLA) can be used to treat lower urinary tract symptoms of benign prostatic hyperplasia in the NHS while more evidence is generated, in people who cannot have ...

Benign prostatic hyperplasia (BPH) is a common condition that affects older people with a prostate. Stromal and epithelial cells increase in number, causing the prostate to get bigger. It often ...

More than 250,000 people undergo a transurethral procedure each year in the U.S., and up to 10% of those people will experience a postoperative infection. But researchers from the University of ...

More than 250,000 people undergo a transurethral procedure each year in the U.S., and up to 10% of those people will experience a postoperative infection. But researchers have discovered an indicator ...

An enlarged prostate, known as benign prostatic hyperplasia (BPH), is a common condition often associated with the natural aging process in men. Dr. Scott Cheney, a Mayo Clinic urologist, says it's a ...

MINNEAPOLIS, Feb. 3, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at ...

Thulium laser transurethral vaporesection of the prostate and transurethral resection of the prostate for benign prostatic hyperplasia resulted in comparable improvements in International Prostate ...

Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...

Following a transurethral resection (TUR) prostatectomy for a benign enlargement, the patient complains of the lack of ejaculation and little emission, although he has a good erection. He does not ...

A phase I/II study of albumin-bound rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer. This is an ASCO Meeting ...